Dermatitis News

ORLANDO — Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab compared with placebo, according to a presenter at the American Academy of Dermatology Annual Meeting

ORLANDO — Nutrition plays a role in the management of atopic dermatitis, according to research presented at the American Academy of Dermatology Annual Meeting.

ORLANDO — Outgoing American Academy of Dermatology President Seemal R. Desai, MD, FAAD, passed the torch to Susan C. Taylor, MD, FAAD, who said she will continue pushing efforts to unify the organization during “a time of great disruption.”

ORLANDO — Atopic dermatitis disease activity remained mild after patients treated with Vtama cream 1% achieved nearly 80 consecutive treatment-free days, according to a presentation at the American Academy of Dermatology Annual Meeting.

ORLANDO — Itching in older patients should not be dismissed as simply dry skin, but rather approached as a complex problem involving numerous causes, according to a speaker at the American Academy of Dermatology Annual Meeting.

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive scratching, among patients of varying ages and races with atopic dermatitis, according to a study.

The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years, according to a press release from the manufacturer.

Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments, according to a study published in Annals of Allergy, Asthma & Immunology.

The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has been cleared by the FDA, Alphyn Biologics announced in a press release.